The impact of the preoperative serum albumin level and postoperative C-reactive protein nadir on the survival of patients with non-metastatic renal cell carcinoma with vessel thrombus after nephrectomy

Current Urology

Volumn 5, Issue 4, 2011, Pages 190-195

  Soga, Norihito ^a   Nishikawa, Kouhei ^b   Yamada, Yasushi ^b   Arima, Kiminobu ^b   Sugimura, Yoshiki ^b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Nephrectomy; Renal cell carcinoma; Tumor thrombus

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY CARCINOMA; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RISK FACTOR; SURVIVAL RATE; TUMOR THROMBUS;

EID: 84856424301     PISSN: 16617649     EISSN: 16617657     Source Type: Journal    
DOI: 10.1159/000327477     Document Type: Article

References (19)

1. Marshall FF, Dietrick DD, Baumgartner WA, Reitz BA: Surgical management of renal cell carcinoma with intracaval neoplastic exten-sion above the hepatic veins. J Urol 1988; 139:1166-1172.
2. Ficarra V, Righetti R, D'Amico A, Rubilotta E, Novella G, Malossini G, Mobilio G: Renal vein and vena cava involvement does not af-fect prognosis in patients with renal cell car-cinoma. Oncology 2001;61:10-15. (Pubitemid 32727582)
3. Bissada NK, Yakout HH, Babanouri A, El-salamony T, Fahmy W, Gunham M, Hull GW, Chaudhary UB: Long-term experience with management of renal cell carcinoma involving the inferior vena cava. Urology 2003;61:89-92. (Pubitemid 36151719)
4. Parekh DJ, Cookson MS, Chapman W, Har-rell F Jr, Wells N, Chang SS, Smith JA Jr: Renal cell carcinoma with renal vein and in-ferior vena caval involvement: clinicopatho-logical features, surgical techniques and out-comes. J Urol 2005;173:1897-1902. (Pubitemid 40675206)
5. Tanaka M, Fujimoto K, Okajima E, Tanaka N, Yoshida K, Hirao Y: Prognostic factors of renal cell carcinoma with extension into infe-rior vena cava. Int J Urol 2008;15:394-398. (Pubitemid 351623890)
6. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Storkel S, van den Berg E, Zbar B: The Hei-delberg classifcation of renal cell tumours. J Pathol 1997;183:131-133
7. Edge SB, Byrd DR, Compton CC, Fritz AG: AJCC Cancer Staging Manual, ed 7. New York, Springer-Verlag, 2010.
8. Oken MM, Creech R H, Tormey DC, Hor-ton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin On-col 1982;5:649-655. (Pubitemid 13149996)
9. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M: Prognostic factors for survival in previously treated pa-tients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-463. (Pubitemid 41079774)
10. Samma S, Yoshida K, Ozono S, Ohara S, Hayashi Y, Tabata S, Uemura H, Iwai A, Hi-rayama A, Hirao Y: Tumor thrombus and mi-crovascular invasion as prognostic factors in renal cell carcinoma. Jpn J Clin Oncol 1991; 21:340-345.
11. McMillan DC, Elahi MM, Sattar N, Anger-son WJ, Johnstone J, McArdle CS: Measure-ment of the systemic infammatory response predicts cancer-specifc and non-cancer sur-vival in patients with cancer. Nutr Cancer 2001;41:64-69. (Pubitemid 34666222)
12. Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC: Evaluation of an infamma-tion-based prognostic score in patients with metastatic renal cancer. Cancer 2007;109: 205-212. (Pubitemid 46106235)
13. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ: Evaluation of cu-mulative prognostic scores based on the sys-temic infammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003;89:1028-1030. (Pubitemid 37239206)
14. Lamb GW, McMillan DC, Ramsey S, Aitchi-son M: The relationship between the preop-erative systemic infammatory response and cancer-specifc survival in patients undergo-ing potentially curative resection for renal clear cell cancer. Br J Cancer 2006;94:781-784.
15. Komai Y, Saito K, Sakai K, Morimoto S: Increased preoperative serum C-reactive pro-tein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 2007;99:77-80. (Pubitemid 44915624)
16. Fujikawa K, Matsui Y, Oka H, Fukuzawa S, Takeuchi H: Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. J Urol 1999;162:1934-1937.
17. Tatokoro M, Saito K, Iimura Y, Fujii Y, Kawakami S, Kihara K: Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J Urol 2008;180:515-519.
18. Johnson TV, Abbasi A, Owen-Smith A, Young AN, Kucuk O, Harris WB, Osunkoya AO, Ogan K, Pattaras J, Nieh PT, Marshall FF, Master VA: Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrec-tomy for renal cell carcinoma. Urology 2010; 76:766e1-5.
19. Saito K, Tatokoro M, Fujii Y, Iimura Y, Koga F, Kawakami S, Kihara K: Impact of C-reactive protein kinetics on survival of pa-tients with metastatic renal cell carcinoma. Eur Urol 2009;55:1145-1154.